A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8504 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Patients

Trial Profile

A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8504 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs MK 8504 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 18 Sep 2017 Last checked against ClinicalTrials.gov record.
    • 13 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 04 Sep 2017 Planned End Date changed from 28 Feb 2018 to 25 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top